EV Biologics, Inc. (YECO)
USD 0.09
(-0.12%)
USD 0.09
(-0.12%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 431.71 Thousand USD | -96.22% |
| 2022 | 11.42 Million USD | -63.55% |
| 2021 | 31.34 Million USD | 246.37% |
| 2020 | 9.04 Million USD | -70.76% |
| 2019 | 30.94 Million USD | 0.0% |
| 2017 | 58.95 Million USD | 61.77% |
| 2016 | 36.44 Million USD | -53.04% |
| 2015 | 77.59 Million USD | 11.56% |
| 2014 | 69.55 Million USD | 21.86% |
| 2013 | 57.07 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 302.24 Thousand USD | -6.49% |
| 2024 Q1 | 323.22 Thousand USD | -25.13% |
| 2024 Q3 | 435.69 Thousand USD | 44.15% |
| 2023 Q3 | 592.22 Thousand USD | 202.64% |
| 2023 Q4 | 431.71 Thousand USD | -27.1% |
| 2023 FY | 431.71 Thousand USD | -96.22% |
| 2023 Q1 | 289.19 Thousand USD | -97.47% |
| 2023 Q2 | 195.68 Thousand USD | -32.33% |
| 2022 Q3 | 22.01 Million USD | -29.27% |
| 2022 FY | 11.42 Million USD | -63.55% |
| 2022 Q4 | 11.42 Million USD | -48.11% |
| 2022 Q1 | 31.64 Million USD | 0.96% |
| 2022 Q2 | 31.12 Million USD | -1.63% |
| 2021 Q1 | 9.14 Million USD | 0.0% |
| 2021 Q4 | 31.34 Million USD | 0.38% |
| 2021 FY | 31.34 Million USD | 246.37% |
| 2021 Q2 | 9.66 Million USD | 5.64% |
| 2021 Q3 | 31.22 Million USD | 223.05% |
| 2020 FY | 9.04 Million USD | -70.76% |
| 2019 FY | 30.94 Million USD | 0.0% |
| 2017 Q1 | 33.27 Million USD | -1.94% |
| 2017 FY | 58.95 Million USD | 61.77% |
| 2017 Q2 | 33.27 Million USD | 0.0% |
| 2017 Q4 | 31.82 Million USD | 0.0% |
| 2016 Q1 | 95.91 Million USD | 6.88% |
| 2016 Q3 | 36.1 Million USD | -0.93% |
| 2016 Q2 | 36.44 Million USD | -62.0% |
| 2016 FY | 36.44 Million USD | -53.04% |
| 2016 Q4 | 33.93 Million USD | -6.0% |
| 2015 Q1 | 71.74 Million USD | 5.71% |
| 2015 FY | 77.59 Million USD | 11.56% |
| 2015 Q4 | 89.74 Million USD | -0.5% |
| 2015 Q3 | 90.19 Million USD | 16.24% |
| 2015 Q2 | 77.59 Million USD | 8.16% |
| 2014 Q4 | 67.86 Million USD | -12.66% |
| 2014 Q1 | 68.17 Million USD | 3.48% |
| 2014 Q2 | 69.55 Million USD | 2.02% |
| 2014 Q3 | 77.7 Million USD | 11.72% |
| 2014 FY | 69.55 Million USD | 21.86% |
| 2013 FY | 57.07 Million USD | 0.0% |
| 2013 Q2 | 57.07 Million USD | 0.0% |
| 2013 Q3 | - USD | -100.0% |
| 2013 Q4 | 65.88 Million USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -18588.918% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 77.953% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 95.909% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 21.808% |
| Rebus Holdings, Inc. | 5000.00 USD | -8534.28% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.668% |
| Qrons Inc. | 420.00 USD | -102689.048% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 43.98% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.455% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 10.164% |
| Skye Bioscience, Inc. | 11.94 Million USD | 96.384% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.889% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 94.02% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -465.411% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.597% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 69.853% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -496.578% |
| Mesoblast Limited | 667.9 Million USD | 99.935% |
| Marizyme, Inc. | 22.01 Million USD | 98.039% |
| Genus plc | 1.02 Billion USD | 99.958% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 68.218% |
| Pharming Group N.V. | 462.85 Million USD | 99.907% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 86.969% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 13.491% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 31.146% |
| ContraFect Corporation | 20.67 Million USD | 97.912% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -10.592% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -12.962% |
| IMV Inc. | 31.33 Million USD | 98.622% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 89.587% |
| MultiCell Technologies, Inc. | 126.22 USD | -341932.958% |
| ONE Bio Corp. | 70.08 Million USD | 99.384% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 54.058% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.664% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | 3.51 Million USD | 87.72% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.773% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -65.232% |
| Biomind Labs Inc. | 73.81 Thousand USD | -484.828% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.903% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 70.203% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.562% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 84.28% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 37.204% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 83.416% |
| GB Sciences, Inc. | 103.44 Thousand USD | -317.349% |
| Alpha Cognition Inc. | 2.45 Million USD | 82.395% |
| HST Global, Inc. | 1526.00 USD | -28190.564% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 56.303% |
| Halberd Corporation | 10.13 Thousand USD | -4161.317% |
| Enzolytics Inc. | 361.7 Million USD | 99.881% |
| Agentix Corp. | 261.39 Thousand USD | -65.16% |
| Resverlogix Corp. | 8.11 Million USD | 94.68% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 77.011% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.99% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.095% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 32.508% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1795.062% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 95.176% |
| AVAX Technologies, Inc. | 7.37 Million USD | 94.148% |
| Zenith Capital Corp. | 7410.00 USD | -5726.1% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.987% |
| Ember Therapeutics, Inc. | 184.00 USD | -234527.174% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -34.153% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -65.177% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 53.477% |
| Kadimastem Ltd | 2.3 Million USD | 81.263% |
| Helix BioMedix, Inc. | 3.02 Million USD | 85.729% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.181% |
| BioStem Technologies, Inc. | 14.56 Million USD | 97.035% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -656.146% |
| LadRx Corporation | 2.3 Million USD | 81.294% |
| Cell Source, Inc. | 195.17 Thousand USD | -121.198% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -22.085% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -22.085% |
| NovAccess Global Inc. | 62.24 Thousand USD | -593.539% |
| Affymax, Inc. | 7.44 Million USD | 94.2% |
| Itoco Inc. | 1.4 Million USD | 69.165% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -351.315% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -307.277% |
| Mobile Lads Corp. | 52.00 USD | -830119.231% |
| CytoDyn Inc. | 11.13 Million USD | 96.123% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -201.957% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2314.508% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -11.996% |
| SYBLEU INC | 330.46 Thousand USD | -30.637% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -5.445% |
| International Stem Cell Corporation | 5.39 Million USD | 91.99% |
| Bioxytran, Inc. | 137.63 Thousand USD | -213.659% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 97.122% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 97.396% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -446.473% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 50.072% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 94.257% |
| Neutra Corp. | 2851.00 USD | -15042.546% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.668% |
| PureTech Health plc | 693.97 Million USD | 99.938% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 94.651% |
| IXICO plc | 15.84 Million USD | 97.275% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 94.787% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.582% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.871% |